Morgan Stanley Maintains Overweight on AbbVie, Raises Price Target to $193
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Terence Flynn maintains an Overweight rating on AbbVie (NYSE:ABBV) and raises the price target from $189 to $193.
October 11, 2023 | 1:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley maintains an Overweight rating on AbbVie and raises the price target from $189 to $193, indicating a positive outlook for the stock.
The raised price target by Morgan Stanley indicates a positive outlook for AbbVie. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100